(NASDAQ: NBIX) Neurocrine Biosciences's forecast annual revenue growth rate of 15.53% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 36.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.09%.
Neurocrine Biosciences's revenue in 2026 is $2,682,700,000.On average, 30 Wall Street analysts forecast NBIX's revenue for 2026 to be $344,084,363,798, with the lowest NBIX revenue forecast at $303,504,144,712, and the highest NBIX revenue forecast at $382,072,234,736. On average, 25 Wall Street analysts forecast NBIX's revenue for 2027 to be $375,092,835,876, with the lowest NBIX revenue forecast at $295,029,160,382, and the highest NBIX revenue forecast at $451,567,106,242.
In 2028, NBIX is forecast to generate $414,177,469,492 in revenue, with the lowest revenue forecast at $347,175,240,436 and the highest revenue forecast at $513,982,873,190.